Main Results of Q1 2025
Bayer’s latest quarterly figures show that the company remains stable despite challenging conditions. In the first quarter of 2025, Bayer recorded a consolidated revenue of 13.74 billion euros, representing a slight decline of 0.1% compared to the previous year. The EBITDA before special items amounted to 4.1 billion euros, indicating a decrease of 7.4% year-on-year. At the same time, the Core EPS dropped by 11.7% to 2.49 euros. Although there was an overall drop in revenue, Bayer’s pharmaceuticals business showed strong growth.
Market Reaction and Forecast
Despite the challenges, Bayer exceeded analysts’ expectations and confirmed its forecast for the current fiscal year. Bayer’s stock is showing a positive trend with a current price of 24.65 euros, reflecting an increase of 3.12%.
Significance for the Audience
As a significant DAX company, Bayer plays an important role in assessing corporate performance and market developments. The current quarterly figures are particularly telling as they underline the company’s ability to remain stable in a changing market environment. This is an indicator of Bayer’s stability and adaptability.
Future Quarterly Results
Bayer plans to publish the next quarterly figures for Q2 2025 on August 6, 2025, with earnings per share estimates at 0.8201 euros. Further releases are scheduled for November 11, 2025 (Q3) and March 3, 2026 (Q4).